eMJA: Inappropriate prescribing for osteoporosis

To the Editor: We believe the current indications for subsidised treatment of osteoporosis specified in the Pharmaceutical Benefits Schedule (PBS) encourage over-prescribing on the one hand, yet, on the other, deny many patients with osteoporosis the treatment they need.

NB: If you are registered with the eMJA, your username is the email address you have provided.
If you don't have a login, click here for subscription options. You will be prompted to create an account upon purchase.

AMA members can login using their AMA username and password.
If you don't know your AMA password, please contact the AMA on 02 6270 5400 or membership@ama.com.au, or try to retrieve your password at this address.

Username:
Password:

Password forgotten? Click here What is my username?

Other articles have cited this article: